Literature DB >> 33555514

HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.

Linsong Mu1, Yeli Wang2, Hailong Su1, Yang Lin1, Wu Sui1, Xiang Yu1, Zhongchuan Lv3.   

Abstract

BACKGROUND: Gastric cancer (GC) is a common leading cause of cancer-related mortality of all malignancies. LncRNA hypoxia-inducible factor-1 alpha antisense RNA-2 (HIF1A-AS2) has been identified to involve in the development of GC. Therefore, we further explored the detailed molecular mechanism of HIF1A-AS2 in GC progression.
METHODS: The expression of HIF1A-AS2, microRNA-429 (miR-429), and programmed cell death ligand 1 (PD-L1) was measured using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell proliferation, migration, and invasion abilities were detected by Cell Counting Kit-8 (CCK-8) or transwell assay. The interaction between miR-429 and HIF1A-AS2 or PD-L1 was confirmed by luciferase reporter assay. Murine xenograft model was established to investigate the role of HIF1A-AS2 in vivo.
RESULTS: HIF1A-AS2 was elevated in GC tissues and cell lines. Functional experiments showed that HIF1A-AS2 knockdown inhibited GC cell proliferation, migration, and invasion in vitro, as well as hindered tumor growth in vivo. Moreover, HIF1A-AS2 directly bound to miR-429 based on bioinformatics prediction and luciferase assay, and inhibition of miR-429 abolished the effects of HIF1A-AS2 knockdown on GC cells. Furthermore, miR-429 directly targeted PD-L1, and overexpression of miR-429 suppressed GC tumorigenesis via PD-L1. Besides that, PD-L1 also performed an oncogenic role in GC cell proliferation and metastasis. Additionally, HIF1A-AS2 could indirectly regulate PD-L1 expression via sponging miR-429.
CONCLUSION: HIF1A-AS2 is a dependable predictor of malignancy and prognosis in GC and functions as an oncogene to promote GC cell proliferation and metastasis by regulating miR-429/PD-L1 axis, indicating a new insight into the search for novel biomarkers and therapeutic strategies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Gastric cancer; HIF1A-AS2; Metastasis; PD-L1; Proliferation; miR-429

Mesh:

Substances:

Year:  2021        PMID: 33555514     DOI: 10.1007/s10620-020-06819-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  4 in total

1.  LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression.

Authors:  M-W Wang; J Liu; Q Liu; Q-H Xu; T-F Li; S Jin; T-S Xia
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-10       Impact factor: 3.507

2.  Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis.

Authors:  Wen-Ming Chen; Ming-de Huang; Rong Kong; Tong-Peng Xu; Er-Bao Zhang; Rui Xia; Ming Sun; Wei De; Yong-Qian Shu
Journal:  Dig Dis Sci       Date:  2015-02-17       Impact factor: 3.199

3.  lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway.

Authors:  G-H Wei; X Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-10       Impact factor: 3.507

4.  miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells.

Authors:  Min Zhang; Bing-Bin Dong; Min Lu; Mei-Juan Zheng; He Chen; Jing-Zhen Ding; A-Man Xu; Yuan-Hong Xu
Journal:  Onco Targets Ther       Date:  2016-03-03       Impact factor: 4.147

  4 in total
  9 in total

1.  N 6 -Methyladenosine-Related Long Non-Coding RNAs Are Identified as a Potential Prognostic Biomarker for Lung Squamous Cell Carcinoma and Validated by Real-Time PCR.

Authors:  Wei Zhang; Qian Zhang; Zhefan Xie; Li Che; Tingting Xia; Xingdong Cai; Shengming Liu
Journal:  Front Genet       Date:  2022-06-03       Impact factor: 4.772

Review 2.  Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.

Authors:  Hyein Jo; Kyeonghee Shim; Dooil Jeoung
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

Review 3.  The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.

Authors:  Wenxiao Jiang; Shuya Pan; Xin Chen; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Cancer       Date:  2021-09-08       Impact factor: 27.401

Review 4.  Prognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers.

Authors:  Xin Qi; Xingqi Chen; Yuanchun Zhao; Jiajia Chen; Beifang Niu; Bairong Shen
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

Review 5.  Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer.

Authors:  Donghoon Kang; In-Ho Kim
Journal:  Biomedicines       Date:  2022-06-10

Review 6.  Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.

Authors:  Ioannis A Vathiotis; Georgia Gomatou; Dimitrios J Stravopodis; Nikolaos Syrigos
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

7.  Serum hsa_tsr016141 as a Kind of tRNA-Derived Fragments Is a Novel Biomarker in Gastric Cancer.

Authors:  Xinliang Gu; Shuo Ma; Bo Liang; Shaoqing Ju
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

8.  lncRNA/miR-29c-Mediated High Expression of LOX Can Influence the Immune Status and Chemosensitivity and Can Forecast the Poor Prognosis of Gastric Cancer.

Authors:  Aitao Nai; Huihui Zeng; Qiong Wu; Zirui He; Shuwen Zeng; Shoaib Bashir; Feng Ma; Jie He; Wei Wan; Meng Xu
Journal:  Front Cell Dev Biol       Date:  2022-01-03

9.  Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis.

Authors:  Alberto Arencibia; Fernando Lanas; Luis A Salazar
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.